B. Riley analyst Kyle Bauser lowered the firm’s price target on OptimizeRx (OPRX) to $13 from $17 and keeps a Buy rating on the shares after the company announced that CEO William Febbo will be departing to pursue other opportunities and that its President was appointed interim CEO while the company conducts a search for a permanent replacement.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- Lake Street reiterates Buy on OptimizeRx after ‘surprising’ CEO departure
- OptimizeRx affirms FY24 guidance, sees revenue, adjusted EBITDA at higher end
- OptimizeRx announces departure of CEO Febbo, appoint Silvestro as interim CEO
- OptimizeRx initiated with an Equal Weight at Stephens
- OptimizeRx lowered to $16 at Roth MKM as revenues miss
Questions or Comments about the article? Write to editor@tipranks.com